Noxopharm (ASX:NOX) Gains as Sofra Moves Towards an FDA Discussion

Aditi Sarkar

05 August 2026 01:22 PM AEST

Noxopharm (ASX:NOX) Gains as Sofra Moves Towards an FDA Discussion

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Noxopharm shares advanced 11.39% to AUD 0.088, with the price reaching AUD 0.088.
Noxopharm requested a pre-investigational-new-drug meeting with the US FDA in July 2026 to discuss the clinical pathway for SOF-SKN.
Trading volume reached 53,434 shares and market capitalisation stood near AUD 27.04mn.
FDA feedback, completion of preclinical work, trial design, external validation of the Sofra platform and funding for clinical development are the principal catalysts.

Noxopharm (ASX:NOX) attracted renewed market attention after rising 11.39% to AUD 0.088. The shares moved between AUD 0.088 and AUD 0.088, with 53,434 units changing hands. The gain placed a fresh spotlight on the company’s latest clinical, regulatory, commercial or corporate development.

The session move sits alongside a one-year return of -26.67%. That longer record provides useful context: a strong day can mark improving expectations, but it does not by itself establish a durable change in value. Future announcements and execution will determine whether buyers remain engaged.

Company Overview

Noxopharm is a biotechnology company developing the Sofra oligonucleotide platform for inflammation-related disorders. SOF-SKN is its lead dermatology programme.

Latest Company Development

Noxopharm requested a pre-investigational-new-drug meeting with the US FDA in July 2026 to discuss the clinical pathway for SOF-SKN. The company said a meeting would generally be expected within about two months. Separately, Hudson Institute researchers received an AUD 1 million government grant for childbirth-injury research involving the Sofra platform.

Share Price and Market Snapshot

NOX closed at AUD 0.088, up 11.39%. It reached AUD 0.088 after trading as low as AUD 0.088, while volume totalled 53,434 shares. At the closing price, the company was valued at approximately AUD 27.04mn. The one-year share-price change was -26.67%, showing that the latest rise occurred within a broader trend that may differ materially from the single session.

What Investors May Watch Next

FDA feedback, completion of preclinical work, trial design, external validation of the Sofra platform and funding for clinical development are the principal catalysts.

The next formal update should help investors judge whether the rally reflects improving fundamentals or short-term positioning. Balance-sheet capacity, delivery against stated milestones and evidence of commercial or clinical progress will remain important alongside the headline catalyst.

Risks

The share-price gain may reverse if expectations run ahead of operational progress.
Clinical, regulatory, commercial or product-development milestones may be delayed or unsuccessful.
Customer adoption, reimbursement or partner execution may develop more slowly than expected.
Capital requirements could increase debt or dilute existing shareholders.
Liquidity and broader market sentiment may amplify price volatility.

FAQs

Q: Why did Noxopharm shares attract attention?

A:The shares rose 11.39% to AUD 0.088 and reached a session high of AUD 0.088.

Q: What is the latest development at Noxopharm?

A:Noxopharm requested a pre-investigational-new-drug meeting with the US FDA in July 2026 to discuss the clinical pathway for SOF-SKN. The company said a meeting would generally be expected within about two months. Separately, Hudson Institute researchers received an AUD 1 million government grant for childbirth-injury research involving the Sofra platform.

Q: What is Noxopharm’s market capitalisation?

A:The market capitalisation was approximately AUD 27.04mn at the stated closing price.

Q: What should investors watch next?

A:FDA feedback, completion of preclinical work, trial design, external validation of the Sofra platform and funding for clinical development are the principal catalysts.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.